Celalettin Ustun

Hematology

1725 W Harrison St Ste 1010
Chicago, IL 60612

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 180 publications

Single dose antithymocyte globulin effectively reduces GVHD and improves survival in patient undergoing myeloablative matched sibling alloHCT.

Single dose antithymocyte globulin effectively reduces GVHD and improves survival in patient undergoing myeloablative matched sibling alloHCT.

Journal: Leukemia & lymphoma

Published: May 05, 2026

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

Journal: Blood advances

Published: March 25, 2026

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

Journal: The Journal of allergy and clinical immunology

Published: December 16, 2025

Exploring the Origin of Cells in the Progression of Primary Myelofibrosis to Acute Myeloid Leukemia Case Report.

Exploring the Origin of Cells in the Progression of Primary Myelofibrosis to Acute Myeloid Leukemia Case Report.

Journal: Case reports in hematology

Published: November 13, 2025

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal: Blood advances

Published: June 20, 2025

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal: Blood advances

Published: June 20, 2025

Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.

Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.

Journal: Journal of the American Academy of Dermatology

Published: March 24, 2025

Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.

Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.

Journal: Blood advances

Published: March 12, 2025

Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study.

Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study.

Journal: British journal of haematology

Published: March 05, 2025

Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.

Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.

Journal: International journal of molecular sciences

Published: June 20, 2024

Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.

Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.

Journal: Blood advances

Published: May 29, 2024

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.

Journal: Blood

Published: May 01, 2024

Showing 1-12 of 180

Last Updated: 09/26/2026